Kai-Oliver Henrich - Concepedia

Author

Kai-Oliver Henrich

German Cancer Research Center

Also Known As

Kai-Oliver Henrich

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

German Cancer Research Center Heidelberg University University Hospital Cologne Ghent University Hospital University Hospital Heidelberg

About

Kai-Oliver Henrich is an author at German Cancer Research Center specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	567
2	Cell Biology	6	6	253
3	Natural Sciences	2	2	148
4	Immunology	1	1	50
5	Molecular Biology	1	1	25

Kai-Oliver Henrich

Publications

Citations

H-Index

Page 1

	Year	Citations
Mutational dynamics between primary and relapse neuroblastomas Alexander Schramm, Johannes Köster, Yassen Assenov, Nature Genetics Tumor HeterogeneityMutational DynamicsPathologyNeuroblastsMedicine	2015	314
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas Frank Westermann, Daniel Muth, Axel Benner, Genome biology	2008	270
Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas Kai-Oliver Henrich, Sebastian Bender, Maral Saadati, Cancer Research Histone ModificationsEpigenetic ChangeDna MethylationMycn Transcriptome IntegrationGlioma	2016	123
Reduced Expression of<i>CAMTA1</i>Correlates with Adverse Outcome in Neuroblastoma Patients Kai-Oliver Henrich, Matthias Fischer, Daniel Mertens, Clinical Cancer Research	2006	64
Transcriptional Repression of <i>SKP2</i> Is Impaired in <i>MYCN</i> -Amplified Neuroblastoma Daniel Muth, Seda Ghazaryan, Isabella Eckerle, Cancer Research	2010	55
The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells Sonja Textor, Felicitas Bossler, Kai-Oliver Henrich, OncoImmunology Nk Cell ReceptorTumor BiologyNk Cell-activating Nkp30Cancer ImmunosurveillanceOncogenic Agent	2016	50
High <i>Skp2</i> Expression Characterizes High-Risk Neuroblastomas Independent of <i>MYCN</i> Status Frank Westermann, Kai-Oliver Henrich, Jun S. Wei, Clinical Cancer Research	2007	49
Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma Isabella Eckerle, Daniel Muth, Julia Batzler, Cancer Letters Cell RegulationGliomaPathologyIsoform Birc5-2bTumor Suppressor	2009	29
ALK positively regulates MYCN activity through repression of HBP1 expression Shana Claeys, Geertrui Denecker, Kaat Durinck, Oncogene Transcriptional RegulationSignal TransductionSignaling PathwayCell RegulationMolecular Regulation	2018	25
Allelic variants of CAMTA1 and FLJ10737 within a commonly deleted region at 1p36 in neuroblastoma Kai-Oliver Henrich, Andreas Claas, Christian Praml, European Journal of Cancer Allelic VariantSomatic VariantMedicineGeneticsDeleted Region	2007	15

Page 1